EVER SINCE A.H. ROBINS' Dalkon Shield proved harmful to thousands of women, Johnson & Johnson has steered clear of the U.S. intrauterine device market--even as its IUD sales boomed overseas. On July 28, though, J&J quietly acquired GynoPharma, which has marketed the ParaGard copper IUD in the U.S. since 1988. GynoPharma CEO Roderick Mackenzie sees the deal as vindication. "People thought I was crazy when I put the IUD on the market," he says. Mackenzie plans to develop more women's products through a new outfit, Gynetics.
Before it's here, it's on the Bloomberg Terminal. LEARN MORE